

May 22, 2019



## **DiaMedica Therapeutics to Present at the 16th Annual Craig-Hallum Institutional Investor Conference on May 29, 2019**

MINNEAPOLIS, May 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 16th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 29, 2019, at the Depot Renaissance Minneapolis Hotel in Minneapolis, MN. Management will be available to participate in one-on-one meetings with investors and attendees can contact their Craig-Hallum representative to arrange a meeting.

### ***About DiaMedica Therapeutics Inc.***

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. The Company currently has an ongoing phase II study in acute ischemic stroke and a phase Ib study in chronic kidney disease. DiaMedica's shares are listed on The Nasdaq Capital Market under the trading symbol "DMAC."

For more information, please visit [www.diamedica.com](http://www.diamedica.com).

### **Contact:**

Scott Kellen  
Chief Financial Officer  
Phone: (763) 496-5118  
[skellen@diamedica.com](mailto:skellen@diamedica.com)

Paul Papi  
Vice President of Business Development  
Phone: (617) 899-5941  
[info@diamedica.com](mailto:info@diamedica.com)



Source: DiaMedica Therapeutics Inc.